Literature DB >> 17150911

Analysis of the interaction between human TLR3 ectodomain and nucleic acids.

Kotaro Fukuda1, Tadayuki Tsujita, Misako Matsumoto, Tsukasa Seya, Hiroshi Sakiyama, Fumiko Nishikawa, Satoshi Nishikawa, Tsunemi Hasegawa.   

Abstract

Toll-like receptor 3 (TLR3) recognizes dsRNA of viral origin and polyriboinosine-polyribocytidylic acid (poly (I:C)). TLR3 mediates the activation of IRF-3 and NF-kappaB and thereby the secretion of type I interferons and inflammatory cytokines. However, the mechanism of this activation is poorly understood. To study the molecular recognition events and biochemical interactions between TLR3 and dsRNA, human TLR3 ectodomain (ECD) fused with a signal peptide at the N-terminus and 6 x His-tag at the C-terminus (TLR3-ECD) was obtained by the baculovirus expression system. To examine the various nucleic acids binding to TLR3-ECD in vitro, a filter binding assay was carried out at pH 4.2-7.6. Interaction of TLR3-ECD with various nucleic acids (particularly dsRNA, in vitro transcripts of tRNA and HCV NS3 aptamer) required an acidic pH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150911     DOI: 10.1093/nass/nrl124

Source DB:  PubMed          Journal:  Nucleic Acids Symp Ser (Oxf)        ISSN: 0261-3166


  3 in total

1.  Cleavage of Toll-like receptor 3 by cathepsins B and H is essential for signaling.

Authors:  Alejandra Garcia-Cattaneo; François-Xavier Gobert; Mélanie Müller; Florent Toscano; Marcella Flores; Aurianne Lescure; Elaine Del Nery; Philippe Benaroch
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-18       Impact factor: 11.205

Review 2.  Recent Advances in Aptamers Targeting Immune System.

Authors:  Piao-Ping Hu
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

3.  Astragalus Polysaccharide Protects Astrocytes from Being Infected by HSV-1 through TLR3/NF-κB Signaling Pathway.

Authors:  Lihong Shi; Fengling Yin; Xiangui Xin; Shumei Mao; Pingping Hu; Chunzhen Zhao; Xiuning Sun
Journal:  Evid Based Complement Alternat Med       Date:  2014-06-26       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.